Medivation Inc (NASDAQ:MDVN) has been downgraded to Neutral in a statement by Citigroup Inc. earlier today.
- Updated: September 16, 2016
Displaying a price of $80.39, Medivation Inc (NASDAQ:MDVN) traded 0.22% lower on the day. With the last stock close up 37.54% relative to the 200-day moving average, compared with the S&P 500 Index which has fallen -0.01% over the date range. MDVN has recorded a 50-day average of $73.40 and two hundred day average of $58.80. Trading volume was was up over the average, with 5,722,621 shares of MDVN changing hands over the typical 3,969,200 shares.
Citigroup Inc. has downgraded Medivation Inc(NASDAQ:MDVN) to Neutral in a statement released 8/22/2016.
Recent Performance Chart:
A total of 17 brokers have released a report on the company. Five analysts rate the stock a strong buy, six analysts rate the company a buy, 10 firms rate the stock a hold, 0 rate the company to underperform, and finally 0 brokeragesrate the stock as sell with a 12-month target price of $62.35
Medivation Inc has a one-year low of $26.41 and a one-year high of $81.15 and has a market capitalization of $0.0.
General Company Details For Medivation Inc (NASDAQ:MDVN)
Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc. (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe and other countries across the world for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company, in collaboration with Astellas, is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. It has developed a small molecule inhibitor of the sterol regulatory element-binding protein, or SREBP, and pathway which it refers to as MDV4463.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.